H.C. Wainwright Upgrades Karyopharm to Buy on Strategic Financing
H.C. Wainwright upgrades Karyopharm to Buy with $15 price target following strategic financing that extends cash runway beyond Phase 3 SENTRY trial results.
/ 932 items
#Healthcare↓
Mind Medicine Earns Bullish Analyst Coverage with $28 Price Target
Needham initiates Buy rating on Mind Medicine with $28 target, citing strong Phase 3 potential for MM120 treatment and $2.5B+ revenue opportunity in $12B market.
Needham Sees Major Upside in Atai Life Sciences' Depression Treatment
Needham initiates Atai Life Sciences with Buy rating and $12 target, projecting BPL-003 could capture 20% market share by 2035 with $2.5B+ in sales.
Barclays Initiates Bullish Coverage on Monopar Therapeutics
Barclays assigns Overweight rating to Monopar Therapeutics with $125 price target, highlighting de-risked biotech opportunities in inflammation, rare disease, and oncology sectors.
AstraZeneca Secures Tariff Relief by Pledging Deep Drug Discounts and $50 Billion U.S. Investment
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.
BofA Slashes Hims & Hers Q4 Forecast 6.5% Below Street
Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.